Van Meerbeeck JP, Fennell DA, De Ruysscher DKM. Small-cell lung cancer. Lancet. 2011;378:1741–55.

Article  PubMed  Google Scholar 

George J, Lim JS, Jang SJ, Cun Y, Ozretić L, Kong G, et al. Comprehensive genomic profiles of small cell lung cancer. Nature. 2015;524(7563):47–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24:4539–44.

Article  PubMed  Google Scholar 

Ortega-Franco A, Ackermann C, Paz-Ares L, Califano R. First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: clinical developments and future directions. ESMO Open. 2021;6:100003.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Früh M, De Ruysscher D, Popat S, Crinò L, Peters S, Felip E. Small-cell lung cancer (SCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annal Oncol. 2013;24:99–105.

Article  Google Scholar 

Lally BE, Urbanic JJ, Blackstock AW, Miller AA, Perry MC. Small cell lung cancer: have we made any progress over the last 25 years? Lear Object Oncol. 2007;12:1096–104.

Google Scholar 

Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379:2220–9. This study results’ have been practice changing, leading to the introduction of a new standard of therapy.

Article  CAS  PubMed  Google Scholar 

Wang J, Zhou C, Yao W, Wang Q, Min X, Chen G, et al. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23:739–47.

Article  CAS  PubMed  Google Scholar 

Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394:1929–39. This study results’ have been practice changing, leading to the introduction of a new standard of therapy.

Article  CAS  PubMed  Google Scholar 

Cheng Y, Han L, Wu L, Chen J, Sun H, Wen G, et al. Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: The ASTRUM-005 Randomized Clinical Trial. JAMA. 2022;328:1223–32.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rudin CM, Durinck S, Stawiski EW, Poirier JT, Modrusan Z, Shames DS, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet. 2012;44:1111–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gazdar AF, Bunn PA, Minna JD. Small-cell lung cancer: what we know, what we need to know and the path forward Nat Rev Cancer. Nat Publ Group. 2017;17(12):725–37.

CAS  Google Scholar 

Peifer M, Fernández-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet. 2012;44:1104–10.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Arcaro A. Targeted therapies for small cell lung cancer: Where do we stand? Crit Rev Oncol Hematol. Elsevier Ireland Ltd. 2015;95:154–64.

Google Scholar 

Bunn PA, Minna JD, Augustyn A, Gazdar AF, Ouadah Y, Krasnow MA, et al. Small cell lung cancer: can recent advances in biology and molecular biology be translated into improved outcomes? Journal of Thoracic Oncology. Lippincott Williams and Wilkins; 2016. 453–74.

Carney DN, Gazdar AF, Bepler G, et al. Establishment and identification of small cell lung cancer cell. Cancer Res. 1985;45:2913–23.

CAS  PubMed  Google Scholar 

Poirier JT, Dobromilskaya I, Moriarty WF, Peacock CD, Hann CL, Rudin CM. Selective tropism of Seneca Valley virus for variant subtype small cell lung cancer. J Natl Cancer Inst. 2013;105:1059–65.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Borromeo MD, Savage TK, Kollipara RK, He M, Augustyn A, Osborne JK, et al. ASCL1 and NEUROD1 reveal heterogeneity in pulmonary neuroendocrine tumors and regulate distinct genetic programs. Cell Rep. 2016;16:1259–72. This study describes a new molecular subtype.

Article  CAS  PubMed  PubMed Central  Google Scholar 

McColl K, Wildey G, Sakre N, Lipka MB, Behtaj M, Kresak A, et al. Reciprocal expression of INSM1 and YAP1 defines subgroups in small cell lung cancer. Oncotarget. 2017;8:73745–56.

Article  PubMed  PubMed Central  Google Scholar 

Qu S, Fetsch P, Thomas A, Pommier Y, Schrump DS, Miettinen MM, et al. Molecular subtypes of primary SCLC tumors and their associations with neuroendocrine and therapeutic markers. J Thorac Oncol. 2022;17:141–53 This study describes a new molecular subtype.

Article  CAS  PubMed  Google Scholar 

Baine MK, Hsieh MS, Lai WV, Egger JV, Jungbluth AA, Daneshbod Y, et al. SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization. J Thorac Oncol. 2020;15:1823–35.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pearsall SM, Humphrey S, Revill M, Morgan D, Frese KK, Galvin M, et al. The Rare YAP1 Subtype of SCLC Revisited in a Biobank of 39 circulating tumor cell patient derived explant models: A Brief Report. J Thorac Oncol. 2020;15:1836–43. This study summarizes the SCLC classification.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Owonikoko TK, Dwivedi B, Chen Z, Zhang C, Barwick B, Ernani V, et al. YAP1 Expression in SCLC defines a distinct subtype with T-cell-inflamed phenotype. J Thorac Oncol. 2021;16:464–76. This study describes a new molecular subtype.

Article  CAS  PubMed  Google Scholar 

Gay CM, Stewart CA, Park EM, Diao L, Groves SM, Heeke S, et al. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell. 2021;39:346-360.e7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

O’Connor MJ. Targeting the DNA Damage Response in Cancer. Mol Cell. 2015;60:547–60.

Article  PubMed  Google Scholar 

Pearl LH, Schierz AC, Ward SE, Al-Lazikani B, Pearl FMG. Therapeutic opportunities within the DNA damage response. Nat Rev Cancer. 2015;15:166–80.

Article  CAS  Google Scholar 

Farago AF, Yeap BY, Stanzione M, Hung YP, Heist RS, Marcoux JP, et al. Combination olaparib and temozolomide in relapsed small-cell lung cancer. Cancer Discov. 2019;9:1372–87.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pietanza MC, Waqar SN, Krug LM, Dowlati A, Hann CL, Chiappori A, et al. Randomized, double-blind, phase ii study of temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer. J Clin Oncol. 2018;36:2386–94.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Woll P, Gaunt P, Danson S, Steele N, Ahmed S, Mulatero C, et al. Olaparib as maintenance treatment in patients with chemosensitive small cell lung cancer (STOMP): A randomised, double-blind, placebo-controlled phase II trial. Lung Cancer. 2022;171:26–33.

Article  CAS  PubMed  Google Scholar 

Owonikoko TK, et al. Randomized phase II trial of cisplatin and etoposide in combination with veliparib or placebo for extensive-stage small-cell lung cancer: ECOG-ACRIN 2511 study. J Clin Oncol. 2019;37(3):222–9. https://doi.org/10.1200/JCO.18.00264.

Article  CAS  PubMed  Google Scholar 

Byers LA, Bentsion D, Gans S, Penkov K, Son C, Sibille A, et al. Veliparib in combination with carboplatin and etoposide in patients with treatment-naïve extensive-stage small cell lung cancer: a phase 2 randomized study. Clin Cancer Res. 2021;27:3884–95.

Article  CAS  PubMed  Google Scholar 

Ai X, Pan Y, Shi J, Yang N, Liu C, Zhou J, et al. efficacy and safety of niraparib as maintenance treatment in patients with extensive-stage sclc after first-line chemotherapy: a randomized, double-blind, phase 3 study. J Thorac Oncol. 2021;16:1403–14.

Article  CAS  PubMed  Google Scholar 

Sen T, Rodriguez BL, Chen L, Della Corte CM, Morikawa N, Fujimoto J, et al. Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer. Cancer Discov. 2019;9:646–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang N, Gao Y, Huang Z, Dai P, Luo Y, Wu Q, et al. PARP inhibitor plus radiotherapy reshapes an inflamed tumor microenvironment that sensitizes small cell lung cancer to the anti-PD-1 immunotherapy. Cancer Lett. 2022;545:215852.

Article  CAS  PubMed  Google Scholar 

Thomas A, Vilimas R, Trindade C, Erwin-Cohen R, Roper N, Xi L, et al. Durvalumab in combination with olaparib in patients with relapsed sclc: results from a phase II study. J Thorac Oncol. 2019;14:1447–57.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nuñez GS, Robles CMG, Giraudon C, Martínez-Leal JF, Compe E, Coin F, et al. Lurbinectedin specifically triggers the degradation of phosphorylated RNA polymerase II and the formation DNA breaks in cancer cells. Mol Cancer Ther. 2016;15:2399–412.

Article